CAJ | 학술논문

目的：探讨脐血干细胞移植治疗乙型肝炎肝硬化的临床疗效。方法：乙型肝炎肝硬化患者48例，分为治疗组25例，在常规保肝治疗的基础上给予脐血干细胞移植治疗，对照组23例，给予常规保肝治疗。观察治疗前，治疗后2、4、12、24周时患者的肝功能、凝血功能、临床症状、体征的改善情况及不良反应。结果：治疗后，治疗组患者白蛋白、胆碱酯酶及凝血酶原活动度均较治疗前及对照组明显改善，差异有统计学意义（P ＜0．05）；对照组白蛋白、胆碱酯酶、凝血酶原活动度水平治疗前后比较差异均无统计学意义（P ＞0．05）；两组患者丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、总胆红素水平治疗前后及两组间比较差异均无统计学意义（P ＞0．05）。治疗4周后，治疗组食欲、乏力、腹胀、腹水的好转情况与对照组比较，差异均有统计学意义（P ＜0．05）。两组患者均未发生严重不良反应及并发症。结论：脐血干细胞移植治疗乙型肝炎肝硬化安全可靠。
목적：탐토제혈간세포이식치료을형간염간경화적림상료효。방법：을형간염간경화환자48례，분위치료조25례，재상규보간치료적기출상급여제혈간세포이식치료，대조조23례，급여상규보간치료。관찰치료전，치료후2、4、12、24주시환자적간공능、응혈공능、림상증상、체정적개선정황급불량반응。결과：치료후，치료조환자백단백、담감지매급응혈매원활동도균교치료전급대조조명현개선，차이유통계학의의（P ＜0．05）；대조조백단백、담감지매、응혈매원활동도수평치료전후비교차이균무통계학의의（P ＞0．05）；량조환자병안산안기전이매、천문동안산안기전이매、총담홍소수평치료전후급량조간비교차이균무통계학의의（P ＞0．05）。치료4주후，치료조식욕、핍력、복창、복수적호전정황여대조조비교，차이균유통계학의의（P ＜0．05）。량조환자균미발생엄중불량반응급병발증。결론：제혈간세포이식치료을형간염간경화안전가고。
Objective To investigate the clinical efficacy of umbilical blood stem cell transplantation (UCBSCT) on the treatment of hepatitis B liver cirrhosis. Methods Forty-eight patients with hepatitis B liver cirrhosis were enrolled and divided into the treatment group and the control group. There were 25 patients in the treatment group , who received UCBSCT treatment based on conventional liver protection treatment and 23 patients in the control group , who received conventional liver protection treatment. The changes of liver function , coagulation function, clinical symptoms, signs and side effects were studied before the treatment and at 2, 4, 12 and 24 weeks post-treatment. Results The levels of albumin, cholinesterase, and prothrombin activity in the treatment group were higher than those before treatment and were higher than those in the control group. The parameters in the control group were not significantly changed before and after the treatment (P > 0.05). The levels of alanine aminotransferase,aspartate aminotransferase,total bilirubin in both two groups were not significantly changed before and after the treatment (P > 0.05). After 4-week treatment,the differences on improvement of appetite , lacking in strength , abdominal distension , ascites were statistically significant in the treatment group compared with the control group (P < 0.05). No adverse reactions were observed in all groups. Conclusion UCBSCT on the treatment of hepatitis B liver cirrhosis is safe and reliable.